Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. The invention is based on the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders, in which the model of administration of the drug comprises the administration to the patient for a minimum of three successive times of a therapeutically effective amount of human therapeutic albumin by plasma exchange and/or intravenous perfusion, independently of the content of A² in the patient's blood.